Navigation Links
NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
Date:8/7/2008

DENVER, Aug. 7 /PRNewswire/ -- Quest Product Development, with partner University of Colorado, has been awarded a $1,000,000 Small Business Technology Transfer grant by the National Institutes of Health (NIH) to continue the development of a next-generation endoscope. MicroFlex technology, derived from aerospace engineering, uses shape metal alloys and micro-actuators that allow active control over the shape of the scope for minimally invasive surgery. Surgeons will guide this ultra-slim 3mm (1/8") diameter scope via a joystick-like control, and can reach previously inaccessible spaces to visualize and diagnose problems. Specialized tools fit through the scope for therapeutic and surgical procedures. Dr. Dale Lawrence, University of Colorado Professor and inventor of the technology, says, "We're excited about the potential of this technology to access small areas of the anatomy."

MicroFlex endoscopes may provide easier out-patient surgery for patients suffering from chronic sinusitis. The sinus application, the first of many potential uses of this technology, was selected due to the prevalence of chronic sinusitis, which effects 33 million Americans, and the challenge of surgery and treatment in these difficult anatomical structures.

Development is being done by Dr. Lawrence's research group at CU Boulder, physicians at the Health Sciences Center and an engineering team from Quest Product Development. A second NIH grant funded research demonstrating that MicroFlex devices can be fabricated as small as 1mm (0.04") diameter, which will allow access deep into areas of the lungs not currently possible, for diagnosis and treatment of lung cancer. Ultimately, MicroFlex technology may provide a useful tool for diagnostic and surgical care for a variety of medical uses including ear-nose-throat, lung, neurosurgery, neonatal and cardiac applications.

MicroFlex is innovative technology with the potential to revolutionize minimally invasive surgerie
'/>"/>

SOURCE Quest Product Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Notice of Initial Distribution of Net Settlement Funds
2. NSF Funds New Entrepreneurship Program
3. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
6. United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research
7. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
8. eResearchTechnology Reports Second Quarter 2008 Results
9. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
10. Abt Associates Ranked One of Top 20 U.S. Market Research Firms
11. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2
Breaking Biology News(10 mins):New understanding of how to prevent destruction of a tumor suppressor 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 1Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 2Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 4Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 5